癌症現在為全球需要面對的議題, 在目前的藥物治療中，化療藥物伴隨著負作用，並且，標靶藥物治療只適用於少部分的癌症病患。經過一連串癌細胞存活率測試，我們發現Tyloxapol具有抑制癌細胞增生的能力，它目前是一種清除支氣管和肺部黏液的用藥。此研究證明Tyloxapol具有潛力成為標靶藥物，未來我們希望能有一些活體研究的證明，將Tyloxapol確實發展成為抗癌藥物的可能性。
Cancer is a lethal cause of morbidity and mortality worldwide. In current therapies, patients suffer from side effects in chemotherapy, and targeted therapy could only be suitable for some of cancer patients. In our study, we explored the possibility of tyloxapol becoming a repurposing drug in cancer therapy. Our results present here should be analyzed in vivo in the future. Hopefully, tyloxapol can be potentially useful as a new targeted therapy drug in CRC treatment.
